secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2023-03-10T23:59:59+00:00
Accession:  0000950170-23-007341
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma holds less than 2% of cash at failed SVB; exposure limited
----------------------------------------------------------------------

- As of March 10, 2023, aTyr holds less than 2% of cash equivalents and investments at SVB.
- Company acknowledges SVB closure and FDIC receivership in SEC filing.
- Remaining >98% of cash is held at other institutions, minimizing direct risk.
- No material financial or operational impact anticipated from SVB failure.
- Disclosure made under Regulation FD on March 10, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023007341/0000950170-23-007341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000095017023007341/life-20230310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer